Trastuzumab deruxtecan – November 2025

• Brand names:
  • Enhertu®
• Pharmaceutical Company:
  • ASTRAZENECA PTY LTD
• Condition/Indication: Gastric or gastroesophageal junction (G/GOJ) cancer
• Meeting Date: November 2025
• Public Summary Document (PSD) May 2025 - November 2025 PBAC Meetings - (PDF 1MB)
• Public Summary Document (PSD) May 2025 - November 2025 PBAC Meetings - (Word 504KB)

Related Public Summary Documents

• Trastuzumab deruxtecan – May 2025